Hydroxyurea

Generic Name
Hydroxyurea
Brand Names
Droxia, Hydrea, Siklos, Xromi
Drug Type
Small Molecule
Chemical Formula
CH4N2O2
CAS Number
127-07-1
Unique Ingredient Identifier
X6Q56QN5QC
Background

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Indication

Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
Associated Therapies
Chemoradiotherapy, Radiation Therapy

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

First Posted Date
2020-03-03
Last Posted Date
2021-01-27
Lead Sponsor
Beni-Suef University
Target Recruit Count
350
Registration Number
NCT04292314
Locations
🇸🇦

Maternity and Children hospital, Mecca, Saudi Arabia

🇪🇬

Health insurance hospital, Banī Suwayf, Egypt

🇪🇬

Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital, Banī Suwayf, Egypt

and more 1 locations

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

First Posted Date
2020-01-03
Last Posted Date
2024-03-22
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
90
Registration Number
NCT04217356
Locations
🇨🇦

St. Paul's Hospital, Vancouver, British Columbia, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 2 locations

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

First Posted Date
2019-10-04
Last Posted Date
2024-11-18
Lead Sponsor
University of Birmingham
Target Recruit Count
586
Registration Number
NCT04116502
Locations
🇬🇧

Royal United Hospital, Bath, United Kingdom

🇬🇧

Belfast City Hospital, Belfast, United Kingdom

🇬🇧

Southmead Hospital, Bristol, United Kingdom

and more 44 locations

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

First Posted Date
2019-05-14
Last Posted Date
2023-08-01
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
202
Registration Number
NCT03948867
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇹🇿

Bugando Medical Centre, Mwanza, Tanzania

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

First Posted Date
2019-03-04
Last Posted Date
2024-05-16
Lead Sponsor
Sanofi
Target Recruit Count
67
Registration Number
NCT03860844
Locations
🇺🇸

Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States

🇲🇽

Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico

🇧🇷

Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

First Posted Date
2019-01-31
Last Posted Date
2022-03-18
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
1
Registration Number
NCT03825341
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

First Posted Date
2019-01-16
Last Posted Date
2024-08-27
Lead Sponsor
Theravia
Target Recruit Count
99
Registration Number
NCT03806452
Locations
🇲🇱

Centre de Recherche et de Lutte contre la Drépanocytose de Bamako (CRLD), Bamako, Mali

🇬🇵

CHU Pointe-à-Pitre/Abymes, Pointe-à-Pitre, Guadeloupe

🇫🇷

CHU d'Angers, Angers, France

and more 18 locations

Hydroxyurea Optimization Through Precision Study

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2018-12-28
Last Posted Date
2023-03-13
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
116
Registration Number
NCT03789591
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Cleveland Clinic Children's, Cleveland, Ohio, United States

🇺🇸

Carle Foundation Hospital, Urbana, Illinois, United States

and more 11 locations

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

First Posted Date
2018-10-23
Last Posted Date
2024-10-30
Lead Sponsor
Children's Hospital Los Angeles
Target Recruit Count
165
Registration Number
NCT03715972
Locations
🇺🇸

CHLA, Los Angeles, California, United States

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

First Posted Date
2018-08-31
Last Posted Date
2024-08-09
Lead Sponsor
Paul Szabolcs
Target Recruit Count
5
Registration Number
NCT03653338
Locations
🇺🇸

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath